Dr Bill (William) Allan, Non-executive Director
Bill is an internationally experienced medical devices executive who has held a number of general management and leadership positions with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker. He has a strong track record of building businesses and launching new products and has worked in Europe, Africa and North America.
Educated at the University of Edinburgh, University of Capetown and Insead Business School, Bill is a mentor at Cambridge University (Judge) Business School and a council member of ABHI (Association of British Healthcare Industries).
Pat Forristal, Chairman & Founder
Pat has over 20 year’s experience in senior leadership roles in the Pharmaceutical and Medical Devices industries. Prior to co-founding SurgaColl, he was Vice President, International Advanced Operations, with the Orthopaedic Division of Stryker Corporation, where he had responsibility for Product Innovation, Business & Process Development and Manufacturing Strategy. His earlier career included 10 years with Pfizer Pharmaceuticals. He is a graduate mechanical engineer from University College Dublin.
Peter Hamer, CEO
Peter has over 25 years international commercial experience, has held a number of senior leadership positions within the orthopaedic/medical device sector and has been responsible for early stage product development, marketing and international sales and distribution in the fields of sports medicine, regenerative medicine and orthopaedics. He worked at Biomet for 20 years in a number of senior roles, including VP Sports Medicine EMEA and with Corin Group as International Sales Director. More recently in the field of regenerative medicine he served as Global Commercial Director, Orthopaedics at Tissue Regenix. Peter brings a deep and current understanding of the global industry that is the focus of SurgaColl’s business.
Antony Odell, Non-executive Director
Antony has an extensive background in the development and commercialisation of both early and late stage medical technology. Over a period of 30 plus years he has worked for major companies such as Johnson & Johnson, Howmedica (Stryker) and Fresenius in a range of senior positions. Latterly he has worked with early stage spin out companies as CEO and has successfully built businesses in a number of fields. In his last position as CEO of Tissue Regenix Group plc he built the company over a period of 9 years to be a listed multi-national organisation and established the strategy that enables its first acquisition in 2017 as well setting it on course for break even.
Antony now works with a number of early stage companies in a variety of Board positions to assist them in optimising the critical early phases of their progress to commercialisation.
Michael Watson, Non-executive Director
Michael Watson has had an over 30-year career in Investment Banking. He has been based in the major financial centres of Asia and Europe as Trader and Manager of Debt Securities and as Syndicate Manager for new debt issuance at major Investment Banks, including 11 years at Deutsche Bank.
He has a BSc (Hons) from the University of Manchester Institute of Science and Technology in European Studies and French. He speaks fluent French, good German, conversational Japanese, basic Polish and Spanish.